Hi there, my son has relapsed MDB and enrolled in the cartcell trial. Found that the risk/benefit was marginal, all but one has passed away. We terminated shortly after signing , my son's medical management and the roadmap has taken a grimm detour as a result. I have learned so much about this and want to share my experience with all but, in all truth the cartcells are unable to penetrate the solid tumor's antigen and hydrocephalus developed due from the excess csf This incident was a code blue when my son had a seizure from the pressure–the csf was extracted via Ommaya and we learned this was to be a common event. The Ommaya will result in tumor seeding as well. This is a palliative , last resort, and death is expected so it is not reported ( an IRB loophole I call it) The researcher states, "IT WONT BE YOU WHO GETS THE CURE BUT THE NEXT GUY." Sadly some believe they are the next guy.